Investigation of the use of a radioactive dye in the diagnosis of a build-up of protein deposits within the heart

Not Applicable

• Conditions: Cardiac amyloidosis including light chain and transthyretin amyloidosis; Cancer; Cardiomyopathy in metabolic diseases

• Registration Number: ISRCTN45011896
• Lead Sponsor: Helsinki University Central Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-02
• Last Update Posted: 12 October 2020
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Previous clinical suspicion of cardiac amyloidosis and currently know the status of their disease (e.g. no amyloidosis, light chain disease, transthyretin)

Exclusion Criteria

1. Pregnancy
2. Age below 18 years
3. Unknown cardiomyopathy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality measured using records from the Finnish national statistical service database at 1, 3 and 5 years

Secondary Outcome Measures

Name	Time	Method
<br> 1. Heart failure measured using patient records diagnoses at 1, 3 and 5 years<br> 2. Heart failure related hospitalizations measured using patient records at 1, 3 and 5 years<br>